GLP-1 Drugs Significantly Reduce Worker Sick Leave by 17%

Tuesday, 21 July 2026, 17:54

GLP-1 drugs have shown potential in reducing workers' sick leave by 17%, according to a recent economic study. This reduction could translate to far-reaching benefits for employees and employers alike. The findings, published by the National Bureau of Economic Research, highlight how these medications improve health outcomes and decrease long-term absences.

Cbsnews — GLP-1 Drugs Significantly Reduce Worker Sick Leave by 17%

Impact of GLP-1 Drugs on Sick Leave

GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a new economic study finds. Researchers found that patients who used the drugs, sold under brand names including Ozempic and Wegovy, took 17% less long-term sick leave than people who didn't use the medications. The study defines long-term sick leave as illness-related absences lasting more than 30 days, according to the paper, published this month by the National Bureau of Economic Research.

Health Benefits of GLP-1 Medications

GLP-1 drugs are prescribed to people with diabetes or obesity.
Research shows these medications improve health significantly.
They play a crucial role in reducing the risk of major adverse cardiovascular events, including heart attacks and strokes.

In conclusion, the integration of GLP-1 drugs into treatment regimens not only benefits individual health but also enhances overall workforce productivity through reduced sick leave.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.